Structured Review

Axon Medchem LLC canertinib
Canertinib, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/canertinib/product/Axon Medchem LLC
Average 90 stars, based on 1 article reviews
Price from $9.99 to $1999.99
canertinib - by Bioz Stars, 2020-09
90/100 stars

Images

Related Articles

other:

Article Title: Activating HER2 mutations in HER2 gene amplification negative breast cancer
Article Snippet: Lapatinib and canertinib were obtained from Axon Medchem (Groningen, The Netherlands).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    lc laboratories canertinib
    Pan-ERBB and NR4A1 inhibition abrogated the Arid1a KO phenotype in vivo. A. Fed state blood glucose measurements following STZ in WT and whole body Arid1a KO mice. 20mg/kg <t>canertinib</t> was administered daily through oral gavage. Compare to Fig. 2F , which did not include canertinib. B. Immunofluorescence for DAPI (blue), insulin (red), and Ki-67 (green) in WT and Arid1a βKO islets before or after PPx in the presence of vehicle, canertinib, or CDIM-8 treatment. C. Quantification of Ki-67 and insulin double positive cell number per islet. Each dot represents an islet. Between 37-75 islets per genotype were counted from 5 to 8 mice per genotype. D. The STRING database predicts an important protein-protein interaction network from differentially overexpressed genes found in RNA-seq data. E. Western blot analysis of c-FOS and p-NR4A1 in mouse islets isolated 6 day post-PPx.
    Canertinib, supplied by lc laboratories, used in various techniques. Bioz Stars score: 91/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/canertinib/product/lc laboratories
    Average 91 stars, based on 9 article reviews
    Price from $9.99 to $1999.99
    canertinib - by Bioz Stars, 2020-09
    91/100 stars
      Buy from Supplier

    90
    Axon Medchem LLC canertinib
    Pan-ERBB and NR4A1 inhibition abrogated the Arid1a KO phenotype in vivo. A. Fed state blood glucose measurements following STZ in WT and whole body Arid1a KO mice. 20mg/kg <t>canertinib</t> was administered daily through oral gavage. Compare to Fig. 2F , which did not include canertinib. B. Immunofluorescence for DAPI (blue), insulin (red), and Ki-67 (green) in WT and Arid1a βKO islets before or after PPx in the presence of vehicle, canertinib, or CDIM-8 treatment. C. Quantification of Ki-67 and insulin double positive cell number per islet. Each dot represents an islet. Between 37-75 islets per genotype were counted from 5 to 8 mice per genotype. D. The STRING database predicts an important protein-protein interaction network from differentially overexpressed genes found in RNA-seq data. E. Western blot analysis of c-FOS and p-NR4A1 in mouse islets isolated 6 day post-PPx.
    Canertinib, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/canertinib/product/Axon Medchem LLC
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    canertinib - by Bioz Stars, 2020-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    Pan-ERBB and NR4A1 inhibition abrogated the Arid1a KO phenotype in vivo. A. Fed state blood glucose measurements following STZ in WT and whole body Arid1a KO mice. 20mg/kg canertinib was administered daily through oral gavage. Compare to Fig. 2F , which did not include canertinib. B. Immunofluorescence for DAPI (blue), insulin (red), and Ki-67 (green) in WT and Arid1a βKO islets before or after PPx in the presence of vehicle, canertinib, or CDIM-8 treatment. C. Quantification of Ki-67 and insulin double positive cell number per islet. Each dot represents an islet. Between 37-75 islets per genotype were counted from 5 to 8 mice per genotype. D. The STRING database predicts an important protein-protein interaction network from differentially overexpressed genes found in RNA-seq data. E. Western blot analysis of c-FOS and p-NR4A1 in mouse islets isolated 6 day post-PPx.

    Journal: bioRxiv

    Article Title: Arid1a loss potentiates pancreatic β-cell regeneration through activation of EGF signaling

    doi: 10.1101/2020.02.10.942615

    Figure Lengend Snippet: Pan-ERBB and NR4A1 inhibition abrogated the Arid1a KO phenotype in vivo. A. Fed state blood glucose measurements following STZ in WT and whole body Arid1a KO mice. 20mg/kg canertinib was administered daily through oral gavage. Compare to Fig. 2F , which did not include canertinib. B. Immunofluorescence for DAPI (blue), insulin (red), and Ki-67 (green) in WT and Arid1a βKO islets before or after PPx in the presence of vehicle, canertinib, or CDIM-8 treatment. C. Quantification of Ki-67 and insulin double positive cell number per islet. Each dot represents an islet. Between 37-75 islets per genotype were counted from 5 to 8 mice per genotype. D. The STRING database predicts an important protein-protein interaction network from differentially overexpressed genes found in RNA-seq data. E. Western blot analysis of c-FOS and p-NR4A1 in mouse islets isolated 6 day post-PPx.

    Article Snippet: Either 20 mg/kg canertinib or 20 mg/kg NR4A1 antagonist C-DIM8-DIM-C-pPhOH (Axon Medchem # Axon 2827) was administered daily through gavage starting a day before PPx until sacrificing mice day 7 post-PPx.

    Techniques: Inhibition, In Vivo, Mouse Assay, Immunofluorescence, RNA Sequencing Assay, Western Blot, Isolation

    Arid1a deficient β-cells have a dependence on increased EGF/Neuregulin signaling. A. Heatmap of differentially expressed genes in WT and KO islets from Arid1a Fl/Fl and Ubc-CreER; Arid1a Fl/Fl mice, isolated after PPx and detected by RNA-Seq (left). Heatmap showing a subset of overexpressed genes in KO islets (right; n = 2 and 2 mice). B. GSEA shows that EGF and NRG1 response genes are upregulated in KO islets. The nominal enrichment score (NES), nominal p-value, and false discovery rate (FDR) q-value are shown within each GSEA plot. C. p-EGFR western blots in MIN6 and BTC6 treated with different doses of EGF. D. p-EGFR western blots in WT MIN6 cells treated with EGF in the presence or absence of erlotinib and canertinib. E. Relative cell numbers for control shGFP and shArid1a MIN6 cells in the presence of canertinib and erlotinib. Shown as % of control cells ( shGFP group treated with DMSO). F. Western blot showing ARID1A levels in MIN6 clones. MIN6 cells were transduced with lenti- CAS9 -blasticidin and either non-targeting lenti-sgRNA ( Gal4 )-puromycin or lenti-sgRNA ( Arid1a )-puromycin. G. MIN6 clone growth over 15 days measured by cell counting. H. mRNA expression of selected genes in Gal4 control and Arid1a KO MIN6 clones as measured by qPCR. I. K-mean clustering of H3K27Ac ChIP-Seq peaks in non-targeting Gal4 , Arid1a heterozygous and Arid1a KO MIN6 clones. J. Annotation of clusters defined by H3K27Ac ChIP-Seq sites by distance to TSS. K. Sample tracks for H3K27Ac ChIP-Seq in control, Arid1a heterozygous and Arid1a KO MIN6 single cell clones at the Nrg4 and Egfr loci.

    Journal: bioRxiv

    Article Title: Arid1a loss potentiates pancreatic β-cell regeneration through activation of EGF signaling

    doi: 10.1101/2020.02.10.942615

    Figure Lengend Snippet: Arid1a deficient β-cells have a dependence on increased EGF/Neuregulin signaling. A. Heatmap of differentially expressed genes in WT and KO islets from Arid1a Fl/Fl and Ubc-CreER; Arid1a Fl/Fl mice, isolated after PPx and detected by RNA-Seq (left). Heatmap showing a subset of overexpressed genes in KO islets (right; n = 2 and 2 mice). B. GSEA shows that EGF and NRG1 response genes are upregulated in KO islets. The nominal enrichment score (NES), nominal p-value, and false discovery rate (FDR) q-value are shown within each GSEA plot. C. p-EGFR western blots in MIN6 and BTC6 treated with different doses of EGF. D. p-EGFR western blots in WT MIN6 cells treated with EGF in the presence or absence of erlotinib and canertinib. E. Relative cell numbers for control shGFP and shArid1a MIN6 cells in the presence of canertinib and erlotinib. Shown as % of control cells ( shGFP group treated with DMSO). F. Western blot showing ARID1A levels in MIN6 clones. MIN6 cells were transduced with lenti- CAS9 -blasticidin and either non-targeting lenti-sgRNA ( Gal4 )-puromycin or lenti-sgRNA ( Arid1a )-puromycin. G. MIN6 clone growth over 15 days measured by cell counting. H. mRNA expression of selected genes in Gal4 control and Arid1a KO MIN6 clones as measured by qPCR. I. K-mean clustering of H3K27Ac ChIP-Seq peaks in non-targeting Gal4 , Arid1a heterozygous and Arid1a KO MIN6 clones. J. Annotation of clusters defined by H3K27Ac ChIP-Seq sites by distance to TSS. K. Sample tracks for H3K27Ac ChIP-Seq in control, Arid1a heterozygous and Arid1a KO MIN6 single cell clones at the Nrg4 and Egfr loci.

    Article Snippet: Either 20 mg/kg canertinib or 20 mg/kg NR4A1 antagonist C-DIM8-DIM-C-pPhOH (Axon Medchem # Axon 2827) was administered daily through gavage starting a day before PPx until sacrificing mice day 7 post-PPx.

    Techniques: Mouse Assay, Isolation, RNA Sequencing Assay, Western Blot, Clone Assay, Transduction, Cell Counting, Expressing, Real-time Polymerase Chain Reaction, Chromatin Immunoprecipitation